The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
High-throughput crystallography for lead discovery in drug design
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Berman, H. M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.235 · Cited by 40,196
Initial sequencing and analysis of the human genome
International Human Genome Sequencing Consortium, Whitehead Institute for Biomedical Research, C. F. G. R., Lander, E. S., Linton, L. M., Birren, B., Nusbaum, C., Zody, M. C., Baldwin, J., Devon, K., Dewar, K., et al. (2001) · Nature · doi:10.1038/35057062 · Cited by 24,216
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Comparative Protein Modelling by Satisfaction of Spatial Restraints
Šali, A., & Blundell, T. L. (1993) · Journal of Molecular Biology · doi:10.1006/jmbi.1993.1626 · Cited by 12,977
Self-citationLipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Automated MAD and MIR structure solution
Terwilliger, T. C., & Berendzen, J. (1999) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444999000839 · Cited by 3,036
Drug Discovery: A Historical Perspective
Drews, J. (2000) · Science · doi:10.1126/science.287.5460.1960 · Cited by 2,760
Goodford, P. J. (1985) · Journal of Medicinal Chemistry · doi:10.1021/jm00145a002 · Cited by 2,634
Automated protein model building combined with iterative structure refinement.
Anastassis Perrakis, A., Morris, R. J., & Lamzin, V. S. (1999) · Nature Structural Biology · doi:10.1038/8263 · Cited by 2,431
Discovering High-Affinity Ligands for Proteins: SAR by NMR
Shuker, S. B., Hajduk, P. J., Meadows, R. P., & Fesik, S. W. (1996) · Science · doi:10.1126/science.274.5292.1531 · Cited by 2,041
Cited by
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915
Docking and scoring in virtual screening for drug discovery: methods and applications
Kitchen, D. B., Decornez, H., Furr, J. R., & Bajorath, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1549 · Cited by 4,150
Improved protein–ligand docking using GOLD
Verdonk, M. L., Cole, J. C., Hartshorn, M. J., Murray, C. W., & Taylor, R. D. (2003) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.10465 · Cited by 3,067
Drug discovery from medicinal plants
Balunas, M. J., & Kinghorn, A. D. (2005) · Life Sciences · doi:10.1016/j.lfs.2005.09.012 · Cited by 1,810
Small-molecule inhibitors of protein–protein interactions: progressing towards the dream
Arkin, M. R., & Wells, J. A. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1343 · Cited by 1,705
Small molecules, big targets: drug discovery faces the protein–protein interaction challenge
Scott, D. E., Bayly, A. R., Abell, C., & Skidmore, J. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.29 · Cited by 1,137
Self-citationNavigating chemical space for biology and medicine
Lipinski, C., & Hopkins, A. (2004) · Nature · doi:10.1038/nature03193 · Cited by 1,002
Rees, D. C., Congreve, Murray, C. W., & Carr, R. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1467 · Cited by 798
Combining docking and molecular dynamic simulations in drug design
Alonso, H., Bliznyuk, A. A., & Gready, J. E. (2006) · Medicinal Research Reviews · doi:10.1002/med.20067 · Cited by 759
Kawate, T., & Gouaux, E. (2006) · Structure · doi:10.1016/j.str.2006.01.013 · Cited by 727
Key Topics in Molecular Docking for Drug Design
Torres, P. H. M., Sodero, A. C. R., Jofily, P., & Silva-Jr, F. P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184574 · Cited by 641
Deng, Z., Chuaqui, C., & Singh, J. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030331x · Cited by 563
Innovative lead discovery strategies for tropical diseases
Nwaka, S., & Hudson, A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2144 · Cited by 521
Polypharmacology by Design: A Medicinal Chemist’s Perspective on Multitargeting Compounds
Proschak, E., Stark, H., & Merk, D. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00760 · Cited by 498
Fragment-Based Approaches in Drug Discovery and Chemical Biology
Scott, D. E., Coyne, A. G., Hudson, S. A., & Abell, C. (2012) · Biochemistry · doi:10.1021/bi3005126 · Cited by 460
Self-citation2.2 Å resolution cryo-EM structure of β-galactosidase in complex with a cell-permeant inhibitor
Bartesaghi, A., Merk, A., Banerjee, S., Matthies, D., Wu, X., Milne, J. L. S., & Subramaniam, S. (2015) · Science · doi:10.1126/science.aab1576 · Cited by 438
A New Method to Detect Related Function Among Proteins Independent of Sequence and Fold Homology
Schmitt, S., Kuhn, D., & Klebe, G. (2002) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)00811-2 · Cited by 423
Application and Limitations of X‐ray Crystallographic Data in Structure‐Based Ligand and Drug Design
Davis, A. M., Teague, S. J., & Kleywegt, G. J. (2003) · Angewandte Chemie International Edition · doi:10.1002/anie.200200539 · Cited by 387
Tethering: Fragment-Based Drug Discovery
Erlanson, D. A., Wells, J. A., & Braisted, A. C. (2004) · Annual Review of Biophysics and Biomolecular Structure · doi:10.1146/annurev.biophys.33.110502.140409 · Cited by 385
Virtual Screening Using Protein−Ligand Docking: Avoiding Artificial Enrichment
Verdonk, M. L., Berdini, V., Hartshorn, M. J., Mooij, W. T. M., Murray, C. W., Taylor, R. D., & Watson, P. (2004) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci034289q · Cited by 380
Ace revisited: A new target for structure-based drug design
Acharya, K. R., Sturrock, E. D., Riordan, J. F., & Ehlers, M. R. W. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1227 · Cited by 342
Ye, L., & Haupt, K. (2004) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-003-2450-8 · Cited by 318
Utilizing graph machine learning within drug discovery and development
Gaudelet, T., Day, B., Jamasb, A. R., Soman, J., Regep, C., Liu, G., Hayter, J. B. R., Vickers, R., Roberts, C., Tang, J., et al. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab159 · Cited by 313
Self-citationWalsh, D. P., & Chang, Y.-T. (2006) · Chemical Reviews · doi:10.1021/cr0404141 · Cited by 296
Applying thermodynamic profiling in lead finding and optimization
Klebe, G. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4486 · Cited by 295
A pipeline approach to single-particle processing in RELION
Fernandez-Leiro, R., & Scheres, S. H. W. (2017) · Acta Crystallographica Section D Structural Biology · doi:10.1107/s2059798316019276 · Cited by 284
Route to three-dimensional fragments using diversity-oriented synthesis
Hung, A. W., Ramek, A., Wang, Y., Kaya, T., Wilson, J. A., Clemons, P. A., & Young, D. W. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1015271108 · Cited by 268
Big physics, small doses: the use of AMS and PET in human microdosing of development drugs
Lappin, G., & Garner, R. C. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1037 · Cited by 260
The role of quantum mechanics in structure-based drug design
Raha, K., Peters, M. B., Wang, B., Yu, N., Wollacott, A. M., Westerhoff, L. M., & Merz, K. M. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.07.006 · Cited by 252
Structural Biology and Drug Discovery of Difficult Targets: The Limits of Ligandability
Surade, S., & Blundell, T. L. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.12.013 · Cited by 230
Self-citationTargeting protein–protein interactions, a wide open field for drug design
Bakail, M., & Ochsenbein, F. (2016) · Comptes Rendus. Chimie · doi:10.1016/j.crci.2015.12.004 · Cited by 117
Targeting Protein–Protein Interactions and Fragment-Based Drug Discovery
Valkov, E., Sharpe, T., Marsh, M., Greive, S., & Hyvönen, M. (2011) · Topics in Current Chemistry · doi:10.1007/128_2011_265 · Cited by 107
Protein-Protein Interactions as Drug Targets
Wendt, M. D. (2012) · Topics in Medicinal Chemistry · doi:10.1007/978-3-642-28965-1_1 · Cited by 9
Metadata
- Authors
- Blundell, T. L., Jhoti, H., & Abell, C.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2002-01
- Volume
- 1
- Issue
- 1
- Pages
- 45-54
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2091223555
- Cited by
- 530
- References
- 70
- FWCI
- 2.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.